loadpatents
Patent applications and USPTO patent grants for BRESCIANI; Alberto.The latest application filed is for "use of perhexiline".
Patent | Date |
---|---|
Use Of Perhexiline App 20170157102 - RUBERTI; Giovina ;   et al. | 2017-06-08 |
Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC Grant 9,371,295 - Altamura , et al. June 21, 2 | 2016-06-21 |
Compounds for use in the treatment of parasitic diseases Grant 9,365,541 - Altamura , et al. June 14, 2 | 2016-06-14 |
Compounds For Use In The Treatment Of Parasitic Diseases App 20150299163 - ALTAMURA; Sergio ;   et al. | 2015-10-22 |
Compounds For Use In The Treatment Of Disorders That Are Ameliorated By Inhibition Of Hdac App 20150218112 - Altamura; Sergio ;   et al. | 2015-08-06 |
Glass sheet Grant D488,565 - Bresciani April 13, 2 | 2004-04-13 |
Glass sheet Grant D480,156 - Bresciani September 30, 2 | 2003-09-30 |
Pattern for sheet glass Grant D474,563 - Bresciani May 13, 2 | 2003-05-13 |
Pattern for sheet glass Grant D474,285 - Bresciani May 6, 2 | 2003-05-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.